In an update provided by the FDA, the agency said its latest testing shows an additional unexpected impurity in three lots of recalled valsartan drug products from Torrent Pharmaceuticals Ltd., of Gujarat, India. The second impurity, N-nitrosodiethylamine (NDEA), is a known animal and suspected human carcinogen.